These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 17933278)

  • 1. Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms.
    Dughera L; Elia C; Navino M; Cisarò F;
    Acta Biomed; 2007 Aug; 78(2):111-6. PubMed ID: 17933278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study.
    Colecchia A; Vestito A; La Rocca A; Pasqui F; Nikiforaki A; Festi D;
    Minerva Gastroenterol Dietol; 2006 Dec; 52(4):349-58. PubMed ID: 17108864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome.
    Tsuchiya J; Barreto R; Okura R; Kawakita S; Fesce E; Marotta F
    Chin J Dig Dis; 2004; 5(4):169-74. PubMed ID: 15612887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
    Drouault-Holowacz S; Bieuvelet S; Burckel A; Cazaubiel M; Dray X; Marteau P
    Gastroenterol Clin Biol; 2008 Feb; 32(2):147-52. PubMed ID: 18387426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention.
    Kajander K; Hatakka K; Poussa T; Färkkilä M; Korpela R
    Aliment Pharmacol Ther; 2005 Sep; 22(5):387-94. PubMed ID: 16128676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: probiotics and prebiotics in irritable bowel syndrome.
    Spiller R
    Aliment Pharmacol Ther; 2008 Aug; 28(4):385-96. PubMed ID: 18532993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating.
    Kim HJ; Vazquez Roque MI; Camilleri M; Stephens D; Burton DD; Baxter K; Thomforde G; Zinsmeister AR
    Neurogastroenterol Motil; 2005 Oct; 17(5):687-96. PubMed ID: 16185307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probiotics and functional gastrointestinal disorders in children.
    Vandenplas Y; Benninga M
    J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S107-9. PubMed ID: 19300120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota.
    Kajander K; Myllyluoma E; Rajilić-Stojanović M; Kyrönpalo S; Rasmussen M; Järvenpää S; Zoetendal EG; de Vos WM; Vapaatalo H; Korpela R
    Aliment Pharmacol Ther; 2008 Jan; 27(1):48-57. PubMed ID: 17919270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.
    Guyonnet D; Chassany O; Ducrotte P; Picard C; Mouret M; Mercier CH; Matuchansky C
    Aliment Pharmacol Ther; 2007 Aug; 26(3):475-86. PubMed ID: 17635382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different segmental transit times in patients with irritable bowel syndrome and "normal" colonic transit time: is there a correlation with symptoms?
    Bouchoucha M; Devroede G; Dorval E; Faye A; Arhan P; Arsac M
    Tech Coloproctol; 2006 Dec; 10(4):287-96. PubMed ID: 17115321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial.
    Cappello G; Spezzaferro M; Grossi L; Manzoli L; Marzio L
    Dig Liver Dis; 2007 Jun; 39(6):530-6. PubMed ID: 17420159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation.
    Agrawal A; Houghton LA; Morris J; Reilly B; Guyonnet D; Goupil Feuillerat N; Schlumberger A; Jakob S; Whorwell PJ
    Aliment Pharmacol Ther; 2009 Jan; 29(1):104-14. PubMed ID: 18801055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study.
    Bittner AC; Croffut RM; Stranahan MC
    Clin Ther; 2005 Jun; 27(6):755-61. PubMed ID: 16117982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study.
    Andriulli A; Neri M; Loguercio C; Terreni N; Merla A; Cardarella MP; Federico A; Chilovi F; Milandri GL; De Bona M; Cavenati S; Gullini S; Abbiati R; Garbagna N; Cerutti R; Grossi E
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S218-23. PubMed ID: 18685503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study.
    Williams EA; Stimpson J; Wang D; Plummer S; Garaiova I; Barker ME; Corfe BM
    Aliment Pharmacol Ther; 2009 Jan; 29(1):97-103. PubMed ID: 18785988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of irritable bowel syndrome improvement: 1-year prospective evaluation in 400 patients.
    Mearin F; Badía X; Balboa A; Benavent J; Caballero AM; Domínguez-Muñoz E; Garrigues V; Piqué JM; Roset M; Cucala M; Figueras M;
    Aliment Pharmacol Ther; 2006 Mar; 23(6):815-26. PubMed ID: 16556184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.
    Pimentel M; Chow EJ; Lin HC
    Am J Gastroenterol; 2000 Dec; 95(12):3503-6. PubMed ID: 11151884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome.
    Silk DB; Davis A; Vulevic J; Tzortzis G; Gibson GR
    Aliment Pharmacol Ther; 2009 Mar; 29(5):508-18. PubMed ID: 19053980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.